Ignite Creation Date:
2024-05-05 @ 10:59 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01225510
Status:
WITHDRAWN
Last Update Posted:
2015-03-11
First Post:
2010-10-19
Brief Title:
A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 2 Trial Of PF-04856884 CVX-060 A Selective Angiopoietin-2 Ang-2 Binding CovX-body In Patients With Recurrent Glioblastoma
Status:
WITHDRAWN
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Angiopoietin-2 Ang-2 is a protein in the body which destabilizes blood vessels and is important in stimulating tumor blood vessels There is evidence suggesting that Ang-2 may be important for the growth and progression of Glioblastoma multiforme GBM PF- 04856884 CVX-060 is a compound which binds Ang-2 and prevents its activity The hypothesis is that PF-04856884 will be safe and effective in patients with recurrent Glioblastoma multiforme GBM
Detailed Description:
Notification of study being cancelled resulted in update in overall status change from not yet recruiting to withdrawn
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None